Compare VIRC & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | ATRA |
|---|---|---|
| Founded | 1950 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 39.1M |
| IPO Year | 1995 | 2014 |
| Metric | VIRC | ATRA |
|---|---|---|
| Price | $6.35 | $5.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 35.3K | ★ 142.1K |
| Earning Date | 03-20-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.61 | ★ 2.93 |
| Revenue | ★ $266,240,000.00 | $128,940,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $10.23 | ★ $1.85 |
| Revenue Growth | N/A | ★ 1404.02 |
| 52 Week Low | $6.00 | $3.92 |
| 52 Week High | $10.62 | $19.15 |
| Indicator | VIRC | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 47.13 |
| Support Level | $6.08 | $4.06 |
| Resistance Level | $6.68 | $5.71 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | 0.02 | 0.38 |
| Stochastic Oscillator | 64.29 | 76.14 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).